We evaluated the potential of AGTR1, the principal receptor for angiotensin II (Ang II) and a member of the G protein-coupled receptor family, for targeted delivery of antisense oligonucleotides (ASOs) in cells and tissues with abundant AGTR1 expression. Ang II peptide ASO conjugates maintained robust AGTR1 signaling and receptor internalization when ASO was placed at the N-terminus of the peptide, but not at C-terminus. Conjugation of Ang II peptide improved ASO potency up to 12- to 17-fold in AGTR1-expressing cells. Additionally, evaluation of Ang II conjugates in cells lacking AGTR1 revealed no enhancement of ASO potency. Ang II peptide conjugation improves potency of ASO in mouse heart, adrenal, and adipose tissues. The data presented in this report add to a growing list of approaches for improving ASO potency in extrahepatic tissues.
Get full access to this article
View all access options for this article.
References
1.
MillerCM, DonnerAJ, BlankEE, EggerAW, KellarBM, OstergaardME, SethPP and HarrisEN. (2016). Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res, 44:2782–2794.
2.
Bennett, CF and SwayzeEE. (2010). RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol, 50:259–293.
3.
GaudetD, AlexanderVJ, BakerBF, BrissonD, TremblayK, SingletonW, GearyRS, HughesSG, VineyNJ, et al. (2015). Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med, 373:438–447.
4.
MillerCM, TanowitzM, DonnerAJ, PrakashTP, SwayzeEE, HarrisEN and SethPP. (2018). Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver. Nucleic Acid Ther, 28:119–127.
5.
PrakashTP, GrahamMJ, YuJ, CartyR, LowA, ChappellA, SchmidtK, ZhaoC, AghajanM, et al. (2014). Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res, 42:8796–8807.
6.
GokirmakT, NikanM, WiechmannS, PrakashTP, TanowitzM and SethPP. (2021). Overcoming the challenges of tissue delivery for oligonucleotide therapeutics. Trends Pharmacol Sci, 42:588–604
7.
SugoT, TeradaM, OikawaT, MiyataK, NishimuraS, KenjoE, Ogasawara-ShimizuM, MakitaY, ImaichiS, et al. (2016). Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control Release, 237:1–13.
8.
AmmalaC, Drury 3rdWJ, KnerrL, AhlstedtI, Stillemark-BilltonP, Wennberg-HuldtC, AnderssonEM, ValeurE, Jansson-LofmarkR, et al. (2018). Targeted delivery of antisense oligonucleotides to pancreatic β-cells. Sci Adv, 4:eaat3386.
9.
KnerrL, PrakashTP, LeeR, DruryWJ, NikanM, FuW, PirieE, MariaLD, ValeurE, et al. (2021). Glucagon like peptide 1 receptor agonists for targeted delivery of antisense oligonucleotides to pancreatic beta cell. J Am Chem Soc, 143:3416–3429.
10.
KonigshoffM, WilhelmA, JahnA, SeddingD, AmarieOV, EulB, SeegerW, FinkL, GuntherA, et al. (2007). The angiotensin II receptor 2 is expressed and mediates angiotensin II signaling in lung fibrosis. Am J Respir Cell Mol Biol, 37:640–650.
11.
UllianME and LinasSL. (1989). Role of receptor cycling in the regulation of angiotensin II surface receptor number and angiotensin II uptake in rat vascular smooth muscle cells. J Clin Invest, 84:840–846.
12.
WangJM, LlonaI and De PotterWP. (1994). Receptor-mediated internalization of angiotensin II in bovine adrenal medullary chromaffin cells in primary culture. Regul Pept, 53:77–86.
13.
BernhemK, KrishnanK, BondarA, BrismarH, AperiaA and Scott.L (2017). At1-receptor response to non-saturating Ang-II concentrations is amplified by calcium channel blockers. BMC Cardiovasc Disord, 17:126.
14.
DainoGL, FrauA, SannaC, RiganoD, DistintoS, MadauV, EspositoF, FanunzaE, BiancoG, et al. (2018). Identification of myricetin as an Ebola virus VP35-double-stranded RNA interaction inhibitor through a novel fluorescence-based assay. Biochemistry, 57:6367–6378.
15.
ZhangH, UnalH, GatiC, HanGW, LiuW, ZatsepinNA, JamesD, WangD, NelsonG, et al. (2015). Structure of the angiotensin receptor revealed by serial femtosecond crystallography. Cell, 161:833–844.
16.
BeautraitA, ParadisJS, ZimmermanB, GiubilaroJ, NikolajevL, ArmandoS, KobayashiH, YamaniL, NamkungY, et al. (2017). A new inhibitor of the β-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling. Nat Commun, 8:15054.
17.
ZhangH, HanGW, BatyukA, IshchenkoA, WhiteKL, PatelN, SadybekovA, ZamlynnyB, RuddMT, et al. (2017). Structural basis for selectivity and diversity in angiotensin II receptors. Nature, 544:327–332.
18.
ZhangJ, LiuX, WangS -Q, LiuG-Y, XuW-R, ChengX-C and WangR-L. (2017). Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan. J Biomol Struct Dyn, 35:2665–2680.
19.
Robertson JrAL. and KhairallahPA. (1971). Angiotensin II. Rapid localization in nuclei of smooth and cardiac muscle. Science, 172:1138–1139.
20.
van KatsJP, van MeegenJR, VerdouwPD, DunckerDJ, MSchalekampADH and DanserAHJ. (2001). Subcellular localization of angiotensin II in kidney and adrenal. J Hypertens, 19:583–589.
21.
RitterSL and HallRA. (2009). Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol, 10:819–830.
22.
PangPS, ButlerJ, CollinsSP, CotterG, DavisonBA, EzekowitzJA, FilippatosG, LevyPD, MetraM, et al. (2017). Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). Eur Heart J, 38:2364–2373.
23.
van KatsJP, ChaiW, DunckerDJ, SchalekampMADH and DanserAHJ. (2005). Adrenal angiotensin: origin and site of generation. Am J Hypertens, 18:1104–1110.
HunyadyL, BaukalAJ, GaborikZ, Olivares-ReyesJA, BorM, SzaszikM, LodgeR, CattKJ and BallaT. (2002). Differential PI 3-kinase dependence of early and late phases of recycling of the internalized AT1 angiotensin receptor. J Cell Biol, 157:1211–1222.
26.
SethPP, SiwkowskiA, AllersonCR, VasquezG, LeeS, PrakashTP, WancewiczEV, WitchellD and SwayzeEE. (2009). Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem, 52:10–13.
CaronKMI, JamesLR, KimH-S, MorhamSG, Sequeira LopezMLS, GomezRA, ReudelhuberTL and SmithiesO. (2002). A genetically clamped renin transgene for the induction of hypertension. Proc Natl Acad Sci U S A, 99:8248–8252.
29.
DoyleDF, BraaschDA, SimmonsCG, JanowskiBA and CoreyDR. (2001). Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length. Biochemistry, 40:53–64.
30.
BaskinJM, PrescherJA, LaughlinST, AgardNJ, ChangPV, MillerIA, LoA, CodelliJA and BertozziCR. (2007). Copper-free click chemistry for dynamic in vivo imaging. Proc Natl Acad Sci U S A, 104:16793–16797.
31.
YanB, ZhangZ, JinD, CaiC, JiaC, LiuW, WangT, LiS, ZhangH, et al. (2016) mTORC1 regulates PTHrP to coordinate chondrocyte growth, proliferation and differentiation. Nat Commun, 7:11151.
32.
FisherGW, FuhrmanMH, AdlerSA, Szent-GyorgyiC, WaggonerAS and JarvikJW. (2014). Self-checking cell-based assays for GPCR desensitization and resensitization. J Biomol Screening, 19:1220–1226.
33.
NikanM, TanowitzM, DwyerCA, JacksonM, GausHJ, SwayzeEE, RigoF, SethPP and PrakashTP. (2020). Targeted delivery of antisense oligonucleotides using neurotensin peptides. J Med Chem, 63:8471–8484.
34.
HutchingsCJ, KoglinM, OlsonWC and MarshallFH. (2017). Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov, 16:787–810.
35.
KaschinaE and UngerT. (2003). Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Pressure, 12:70–88.
36.
JinZ-N and WeiY-X. (2016). Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. J Geriatr Cardiol, 13:333–343.
37.
FelkerGM, ButlerJ, CollinsSP, CotterG, DavisonBA, EzekowitzJA, FilippatosG, LevyPD, MetraM, et al. (2015). Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail 3:193–201.
38.
DomazetI, HolleranBJ, RichardA, VandenbergheC, LavigneP, EscherE, LeducR and GuillemetteG. (2015). Characterization of angiotensin II molecular determinants involved in AT1 receptor functional selectivity. Mol Pharmacol, 87:982–995.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
